Clinuvel Pharmaceuticals Limited (CLVLF)
USD 7.45
(2.05%)
USD 7.45
(2.05%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 28.11 Million AUD | -3.34% |
| 2023 | 29.08 Million AUD | 58.14% |
| 2022 | 18.39 Million AUD | 87.08% |
| 2021 | 9.83 Million AUD | 24.85% |
| 2020 | 7.87 Million AUD | 52.42% |
| 2019 | 5.16 Million AUD | 48.07% |
| 2018 | 3.48 Million AUD | 10.3% |
| 2017 | 3.16 Million AUD | 37.3% |
| 2016 | 2.3 Million AUD | -5.53% |
| 2015 | 2.43 Million AUD | 41.3% |
| 2014 | 1.72 Million AUD | -12.64% |
| 2013 | 1.97 Million AUD | -16.22% |
| 2012 | 2.35 Million AUD | -37.24% |
| 2011 | 3.75 Million AUD | 21.97% |
| 2010 | 3.08 Million AUD | -32.48% |
| 2009 | 4.56 Million AUD | 44.56% |
| 2008 | 3.15 Million AUD | 29.73% |
| 2007 | 2.43 Million AUD | -21.06% |
| 2006 | 3.08 Million AUD | 18.48% |
| 2005 | 2.6 Million AUD | 86.82% |
| 2004 | 1.39 Million AUD | 160.05% |
| 2003 | 535.45 Thousand AUD | 153.98% |
| 2002 | 210.82 Thousand AUD | -33.76% |
| 2001 | 318.26 Thousand AUD | 157.62% |
| 2000 | 123.53 Thousand AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 33.03 Million AUD | 13.58% |
| 2024 Q2 | 33.03 Million AUD | 0.0% |
| 2024 Q4 | 28.11 Million AUD | 0.0% |
| 2024 FY | 28.11 Million AUD | -3.34% |
| 2023 Q2 | 21.12 Million AUD | 0.0% |
| 2023 Q3 | 29.08 Million AUD | 37.69% |
| 2023 Q1 | 21.12 Million AUD | 14.85% |
| 2023 Q4 | 29.08 Million AUD | 0.0% |
| 2023 FY | 29.08 Million AUD | 58.14% |
| 2022 Q2 | 8.36 Million AUD | 0.0% |
| 2022 Q4 | 18.39 Million AUD | 0.0% |
| 2022 Q1 | 8.36 Million AUD | -14.94% |
| 2022 Q3 | 18.39 Million AUD | 119.94% |
| 2022 FY | 18.39 Million AUD | 87.08% |
| 2021 FY | 9.83 Million AUD | 24.85% |
| 2021 Q4 | 9.83 Million AUD | 0.0% |
| 2021 Q1 | 9.79 Million AUD | 24.42% |
| 2021 Q3 | 9.83 Million AUD | 0.35% |
| 2021 Q2 | 9.79 Million AUD | 0.0% |
| 2020 Q3 | 9.47 Million AUD | 133.93% |
| 2020 Q2 | 4.05 Million AUD | 0.0% |
| 2020 FY | 7.87 Million AUD | 52.42% |
| 2020 Q1 | 4.05 Million AUD | -21.59% |
| 2020 Q4 | 7.87 Million AUD | -16.9% |
| 2019 Q4 | 5.16 Million AUD | 0.0% |
| 2019 Q1 | 2.56 Million AUD | -26.6% |
| 2019 Q2 | 2.56 Million AUD | 0.0% |
| 2019 Q3 | 5.16 Million AUD | 101.72% |
| 2019 FY | 5.16 Million AUD | 48.07% |
| 2018 Q3 | 3.47 Million AUD | 25.47% |
| 2018 Q4 | 3.48 Million AUD | 0.51% |
| 2018 Q1 | 2.76 Million AUD | -12.54% |
| 2018 FY | 3.48 Million AUD | 10.3% |
| 2018 Q2 | 2.76 Million AUD | 0.0% |
| 2017 Q4 | 3.16 Million AUD | 0.49% |
| 2017 FY | 3.16 Million AUD | 37.3% |
| 2017 Q3 | 3.14 Million AUD | 38.45% |
| 2017 Q2 | 2.27 Million AUD | 0.0% |
| 2017 Q1 | 2.27 Million AUD | -1.32% |
| 2016 FY | 2.3 Million AUD | -5.53% |
| 2016 Q4 | 2.3 Million AUD | 0.67% |
| 2016 Q3 | 2.28 Million AUD | -8.11% |
| 2016 Q2 | 2.49 Million AUD | 0.0% |
| 2016 Q1 | 2.49 Million AUD | 2.12% |
| 2015 Q2 | 1.79 Million AUD | 0.0% |
| 2015 FY | 2.43 Million AUD | 41.3% |
| 2015 Q1 | 1.79 Million AUD | 3.79% |
| 2015 Q4 | 2.43 Million AUD | 0.14% |
| 2015 Q3 | 2.43 Million AUD | 35.95% |
| 2014 FY | 1.72 Million AUD | -12.64% |
| 2014 Q2 | 1.81 Million AUD | 0.0% |
| 2014 Q1 | 1.81 Million AUD | -8.15% |
| 2014 Q3 | 1.71 Million AUD | -5.3% |
| 2014 Q4 | 1.72 Million AUD | 0.45% |
| 2013 Q4 | 1.97 Million AUD | 1.5% |
| 2013 Q3 | 1.94 Million AUD | 0.0% |
| 2013 FY | 1.97 Million AUD | -16.22% |
| 2012 Q4 | 2.35 Million AUD | 0.0% |
| 2012 FY | 2.35 Million AUD | -37.24% |
| 2011 Q4 | 3.75 Million AUD | 0.0% |
| 2011 FY | 3.75 Million AUD | 21.97% |
| 2010 FY | 3.08 Million AUD | -32.48% |
| 2010 Q4 | 3.08 Million AUD | 0.0% |
| 2009 Q4 | 4.56 Million AUD | 0.0% |
| 2009 FY | 4.56 Million AUD | 44.56% |
| 2008 FY | 3.15 Million AUD | 29.73% |
| 2008 Q4 | 3.15 Million AUD | 0.0% |
| 2007 Q4 | 2.43 Million AUD | 0.0% |
| 2007 FY | 2.43 Million AUD | -21.06% |
| 2006 FY | 3.08 Million AUD | 18.48% |
| 2006 Q4 | 3.08 Million AUD | 0.0% |
| 2005 Q4 | 2.6 Million AUD | 0.0% |
| 2005 FY | 2.6 Million AUD | 86.82% |
| 2004 FY | 1.39 Million AUD | 160.05% |
| 2004 Q4 | 1.39 Million AUD | 0.0% |
| 2003 Q4 | 535.45 Thousand AUD | 0.0% |
| 2003 FY | 535.45 Thousand AUD | 153.98% |
| 2002 Q4 | 210.82 Thousand AUD | 0.0% |
| 2002 FY | 210.82 Thousand AUD | -33.76% |
| 2001 FY | 318.26 Thousand AUD | 157.62% |
| 2000 FY | 123.53 Thousand AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 50.26 Million USD | 44.071% |
| Skye Bioscience, Inc. | 14.07 Million USD | -99.771% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 52.364% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -3375.815% |
| Qrons Inc. | 1.48 Million USD | -1788.355% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.9 Million USD | -76.754% |
| CSL Limited | 18.62 Billion USD | 99.849% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 61.209% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -196.983% |
| Regen BioPharma, Inc. | 5.45 Million USD | -415.1% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 62.477% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -62796.418% |
| Rebus Holdings, Inc. | 5.24 Million USD | -436.287% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -102375.788% |
| Neon Bloom, Inc. | 1.22 Million USD | -2192.602% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -13878.094% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 47.262% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -193.385% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -6568.481% |
| SQZ Biotechnologies Company | 50.03 Million USD | 43.819% |
| Intellipharmaceutics International Inc. | 12 Million USD | -134.097% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -629.917% |
| Mesoblast Limited | 188.44 Million USD | 85.082% |
| Marizyme, Inc. | 26.67 Million USD | -5.385% |
| Genus plc | 485 Million USD | 94.204% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -381.157% |
| Pharming Group N.V. | 244.07 Million USD | 88.482% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -1298.526% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -1017.191% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -639.794% |
| ContraFect Corporation | 32.53 Million USD | 13.583% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -1318.87% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -634.451% |
| IMV Inc. | 37.93 Million USD | 25.89% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -138.68% |
| MultiCell Technologies, Inc. | 1617.67 USD | -1737719.395% |
| ONE Bio Corp. | 27.49 Million USD | -2.242% |
| Accustem Sciences Inc. | 1.07 Million USD | -2504.815% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 63.687% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -1229.138% |
| Q BioMed Inc. | 8.13 Million USD | -245.658% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 66.103% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -446.288% |
| Biomind Labs Inc. | 1.49 Million USD | -1775.881% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 76.321% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -210.9% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -52.755% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -1860.593% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -19684.076% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -389.263% |
| GB Sciences, Inc. | 5.41 Million USD | -418.909% |
| Alpha Cognition Inc. | 7.16 Million USD | -292.367% |
| HST Global, Inc. | 593.59 Thousand USD | -4635.936% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -2132.556% |
| Halberd Corporation | 728.71 Thousand USD | -3757.754% |
| Enzolytics Inc. | 365.26 Million USD | 92.304% |
| Agentix Corp. | 2.51 Million USD | -1019.76% |
| Resverlogix Corp. | 67.39 Million USD | 58.288% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -3251.748% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 93.682% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -1540.151% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -13.603% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -136.175% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -667.01% |
| AVAX Technologies, Inc. | 3.99 Million USD | -603.905% |
| Zenith Capital Corp. | 27.56 Thousand USD | -101870.267% |
| Genscript Biotech Corporation | 1.32 Billion USD | 97.88% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -11679.473% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -652.809% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -4029.08% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -936.722% |
| Kadimastem Ltd | 3.5 Million USD | -702.09% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -41902.993% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -5949.547% |
| LadRx Corporation | 2.2 Million USD | -1177.52% |
| Cell Source, Inc. | 15.8 Million USD | -77.85% |
| Regen BioPharma, Inc. | 5.45 Million USD | -415.1% |
| NovAccess Global Inc. | 7.86 Million USD | -257.628% |
| Affymax, Inc. | 8.87 Million USD | -216.9% |
| Itoco Inc. | 1.65 Million USD | -1600.521% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -1270.28% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -364.741% |
| Mobile Lads Corp. | 1.31 Million USD | -2040.255% |
| CytoDyn Inc. | 127.89 Million USD | 78.019% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -67155.635% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -1694.726% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -154.517% |
| SYBLEU INC | 681.41 Thousand USD | -4025.572% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -360.712% |
| International Stem Cell Corporation | 5.27 Million USD | -432.73% |
| Bioxytran, Inc. | 3.24 Million USD | -765.123% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -4392.135% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -508.868% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 31.427% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -26.262% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -1287.991% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -413.183% |
| Neutra Corp. | 973.52 Thousand USD | -2787.657% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 3.112% |
| PureTech Health plc | 125.58 Million USD | 77.615% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -648.237% |
| IXICO plc | 1.9 Million USD | -1379.361% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -36.939% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 72.792% |
| CSL Limited | 18.62 Billion USD | 99.849% |
| Cellectis S.A. | 249.36 Million USD | 88.727% |